Uncommon

What Uncommon does

Uncommon is a Cambridge, UK-based biotechnology company that originated in the cultivated meat sector, developing cultivated pork products using proprietary RNA technology and nucleic acid delivery techniques for cell programming and differentiation. The company combined plant-based protein expertise with cell-cultured meat methods to produce pork without animal slaughter, targeting the alternative protein market with a value proposition centered on environmental sustainability and animal welfare.

The business model was originally structured around commercial sale of cultivated meat products, with a $30 million Series A round raised in June 2023 (led by Balderton Capital and Lowercarbon Capital, with participation from Sam Altman) intended to fund regulatory approval, production scale-up, and team expansion. The company employed between 51 and 100 staff, including a CSO, VP of Operations, and Head of R&D, indicating meaningful R&D and bioprocess capacity.

In 2025, Uncommon executed a strategic pivot: it sold its cultivated meat platform to Vow (an alternative meat producer) and subsequently launched SymphoRNA, a new platform leveraging its nucleic acid delivery technology. The company now positions itself around SymphoRNA rather than end-product meat sales, with no disclosed revenue, customers, or distribution channels for the new platform.

Name

Uncommon

Legal name

Uncommon

Website

https://uncommonbio.co

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Uncommon is a Cambridge-based biotech company that has pivoted from cultivated pork production using RNA technology to a nucleic acid delivery platform called SymphoRNA, following the 2025 sale of its cultivated meat platform to Vow.

Ownership category

akta.pro rank

Product category

Biotechnology - Nucleic Acid Delivery

NAICS

Animal Slaughtering and Processing (3116)

SIC

Meat Packing Plants (2011), Food And Kindred Products (2000)

akta.pro industry

PRIMARYAFANAKAJ

Hybrid Meat Products (Blended Plant-Based + Cultivated/Conventional)

Agriculture & Food Production/Meat, Poultry & Seafood Processing/Meat Alternatives (Plant-Based and Cultivated)

SECONDARYAFANAKAO

Finished Meat-Alternative Prepared Foods (Nuggets, Burgers, Sausages, Ready Meals)

Agriculture & Food Production/Meat, Poultry & Seafood Processing/Meat Alternatives (Plant-Based and Cultivated)

Keywords

• Cultivated meat technology
• Nucleic acid delivery
• RNA technology platform
• Alternative protein production
• Biotechnology platform

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Cultivated Meat Products: The company is developing cultivated pork products for commercial sale. Revenue model is likely to involve product sales once regulatory approval is obtained and production is scaled up.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Uncommon is a Cambridge-based biotechnology company that originally developed cultivated pork products using proprietary RNA technology and nucleic acid delivery. After selling its cultivated meat platform to Vow, the company has pivoted to launch SymphoRNA, a nucleic acid delivery technology platform representing its next chapter of operation.

Product overview

Uncommon is a biotechnology company that has transitioned from cultivated meat production to nucleic acid delivery technology. After selling their cultivated platform to Vow, the company launched SymphoRNA as their primary product. The company previously developed RNA technology for cultivated pork products and had raised $30 million in Series A funding for scaling artificial pork meat production using plant-based and cell-cultured meat expertise.

Differentiator

Problem solved

Functional benefit

Brands

• SymphoRNA: A new platform launched by Uncommon focusing on world-class nucleic acid delivery technology.

Products and services

• SymphoRNA A nucleic acid delivery technology platform developed by Uncommon, representing the company's next-generation direction following the divestiture of its cultivated meat business to Vow. Targeted at enabling efficient cell programming using proprietary nucleic acid delivery capabilities.
• Cultivated Pork Products Cultivated pork products developed using RNA technology and cell-cultured meat expertise, designed to deliver meat without animal slaughter for consumers seeking sustainable alternative protein. The platform was sold to Vow in 2025.

Quantifiable outcome

• Development of cultivated pork products without animal slaughter

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• VowcoreStrategic or Co-development PartnerAcquired Uncommon's cultivated platform. This represents a strategic transaction where Vow gained access to Uncommon's cultivated meat technology and platform capabilities. Uncommon has since pivoted to focus on its nucleic acid delivery technology under the SymphoRNA brand.

Scale indicators1 record

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Moderna: Massachusetts-based biotech company whose mRNA and lipid nanoparticle delivery platform is the dominant commercial example of nucleic acid delivery at scale. Relevant broad incumbent given Uncommon's post-pivot SymphoRNA nucleic acid delivery focus.
• Impossible Foods: California-based plant-based meat company producing beef and pork alternatives. Broad incumbent in alternative protein with overlapping end-markets to Uncommon's original cultivated pork mission.

Direct peers

• Aleph Farms: Israel-based cultivated beef company using proprietary cell-cultivation platforms. Comparable to Uncommon's cultivated meat origins and RNA/cell programming technology approach.
• Eat Just: San Francisco-based food technology company best known for its cultivated chicken product (GOOD Meat) and plant-based JUST Egg. Directly comparable as a cultivated meat peer that combines cell-cultured and plant-based protein expertise.
• Future Meat Technologies: Israel-based cultivated meat company producing cell-cultured chicken, beef, lamb, and pork. Directly comparable as a cultivated meat peer with multi-species production capabilities similar to Uncommon's original cultivated pork focus.
• Upside Foods: Emeryville-based cultivated meat company (formerly Memphis Meats) producing cell-cultured poultry, beef, and duck. Direct peer in cultivated protein technology with similar regulatory approval milestones.
• Vow: Australia-based cultivated meat company that acquired Uncommon's cultivated meat platform in 2025. Most directly comparable peer as it now owns and continues to develop the exact technology Uncommon sold.
• BlueNalu: San Diego-based cultivated seafood company producing cell-cultured fish products. Comparable peer in the cultivated meat space with similar production scale-up and regulatory challenges.
• Mosa Meat: Netherlands-based cultivated beef company founded by the pioneers of cell-cultured meat. Directly comparable to Uncommon as a European cultivated meat peer pursuing regulatory approval and scale-up.
• Wildtype: San Francisco-based company developing cultivated seafood, starting with salmon. Comparable alternative protein peer pursuing cultivated cell-based products through regulatory pathways.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/uncommonbio
• LinkedInlinkedin.com/company/uncommonbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Uncommon